Advertisement

Efficacy of the Glucosidase Inhibitor Acarbose Compared to the Sulfonylurea Glisoxepide on Metabolic Control in Diet-Treated Type II Diabetics

  • R. Mies
  • M. Spengler
  • U. Henke
  • K. Boehme
Conference paper

Abstract

α-Glucosidase inhibition is a new principle in the treatment of diabetes mellitus. To compare this new principle with the well-established sulfonylurea therapy of type II diabetes, we treated 20 type II diabetics with the α-glucosidase inhibitor acarbose or the sulfonylurea glisoxepide in a double-dummy, double-blind, crossover study with 4-week drug-free pretreatment, 2 treatment periods of 8 weeks, with 4 weeks of washout. Dosage per day was acarbose 3 × 50 mg in week 1, 3 × 100 mg in week 2, 3 × 200 mg in weeks 3–8, glisoxepide 2 × 4 mg. Nine male and 11 female patients treated solely by means of diet (6665 ± 1217 kJ/day) were included (age, 62 ± 9 years; Broca index, 1.05 ± 0.07; median duration of diabetes, 6 years).

Keywords

Blood Glucose Metabolic Control Blood Glucose Control Gastrointestinal Side Effect Postprandial Blood Glucose 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • R. Mies
    • 1
  • M. Spengler
    • 2
  • U. Henke
    • 1
  • K. Boehme
    • 2
  1. 1.Department of Internal MedicineSt. Antonius HospitalKöln 51Germany
  2. 2.Pharma Research CentreBayer AGWuppertal 1Germany

Personalised recommendations